Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity

Journal of Clinical Virology

Volumn 74, Issue , 2016, Pages 57-60

  Herling, Marco ^a   Schroder L ^a   Awerkiew, Sabine ^a   Chakupurakal, Geothy ^a   Holtick, Udo ^a   Kaiser, Rolf ^a   Pfister, Herbert ^a   Scheid, Christof ^a   Di Cristanziano, Veronica ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus; Multidrug resistance; QuantiFERON CMV assay

Indexed keywords

BRINCIDOFOVIR; CREATININE; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; PREDNISOLONE; STEROID; TACROLIMUS; VALGANCICLOVIR; ANTIVIRUS AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; COLITIS; COLONOSCOPY; COMPASSIONATE USE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL GRAFT VERSUS HOST DISEASE; GENE MUTATION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; OFF LABEL DRUG USE; PANCYTOPENIA; PERSISTENT INFECTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; UNRELATED DONORS; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; TISSUE DONORS; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84951818492     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.11.033     Document Type: Article

References (26)

1. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2013, 362:1375-1377. 10.1016/s0140-6736(03)14634-x.
2. Tzannou I., Leen A.M. Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin. Transl. Immunol. 2014, 3:e11. 10.1038/cti.2014.2.
3. Mori T., Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int. J. Hematol. 2010, 91:588-595. 10.1007/s12185-010-0569-x.
4. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 2009, 22:76-98. 10.1128/CMR.34-08.
5. Cihlar T., Fuller M.D., Cherrington J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 1998, 72:5927-5936.
6. Marty F.M., Winston D.J., Rowley S.D., Vance E., Papanicolaou G.A., Mullane K.M., Brundage T.M., Robertson A.T., Godkin S., Momméja-Marin H., Boeckh M., CMX001-201 Clinical Study Group CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 2013, 369:1227-1236. 10.1056/NEJMoa1303688.
7. Boeckh M., Murphy W.J., Peggs K.S. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol. Blood Marrow Transplant. 2015, 21:24-29. 10.1016/j.bbmt.2014.11.002.
8. Levi M.E., Mandava N., Chan L.K., Weinberg A., Olson J.L. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl. Infect. Dis. 2006, 8:38-43.
9. Gohring K., Hamprecht K., Jahn G. Antiviral drug- and multidrug resistance in cytomegalovirus infected SCT patients. Comput. Struct. Biotechnol. J. 2015, 13:153-159. 10.1016/j.csbj.2015.01.003.
10. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 2010, 23:689-712. 10.1128/cmr.00009-10.
11. Gohring K., Wolf D., Bethge W., Mikeler E., Faul C., Vogel W., Vohringer M.C., Jahn G., Hamprecht K. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation. J. Clin. Virol. 2013, 57:43-49. 10.1016/j.jcv.2013.01.003.
12. Chevillotte M., von Einem J., Meier B.M., Lin F.M., Kestler H.A., Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antivir. Res. 2010, 85:318-327. 10.1016/j.antiviral.2009.10.004.
13. Boivin G., Gilbert C., Gaudreau A., Greenfield I., Sudlow R., Roberts N.A. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 2001, 184:1598-1602.
14. Lurain N.S., Bhorade S.M., Pursell K.J., Avery R.K., Yeldandi V.V., Isada C.M., Robert E.S., Kohn D.J., Arens M.Q., Garrity E.R., Taege A.J., Mullen M.G., Todd K.M., Bremer J.W., Yen-Lieberman B. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J. Infect. Dis. 2002, 186:760-768.
15. Boutolleau D., Deback C., Bressollette-Bodin C., Varnous S., Dhedin N., Barrou B., Vernant J.P., Gandjbakhch I., Imbert-Marcille B.M., Agut H. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antivir. Res. 2009, 81:174-179. 10.1016/j.antiviral.2008.11.003.
16. Oshima K., Kanda Y., Kako S., Asano-Mori Y., Watanabe T., Motokura T., Chiba S., Shiraki K., Kurokawa M. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J. Med. Virol. 2008, 80:1769-1775. 10.1002/jmv.21277.
17. Schnepf N., Dhedin N., Mercier-Delarue S., Andreoli A., Mamez A.C., Ferry C., Deback C., Ribaud P., Robin M., Socie G., Simon F., Mazeron M.C. Dynamics of cytomegalovirus populations harbouring mutations in genes UL54 and UL97 in a haematopoietic stem cell transplant recipient. J. Clin. Virol. 2013, 58:733-736. 10.1016/j.jcv.2013.10.007.
18. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., Silini E., Gerna G. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 1996, 70:1390-1395.
19. Sarasini A., Baldanti F., Furione M., Percivalle E., Brerra R., Barbi M., Gerna G. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J. Med. Virol. 1995, 47:237-244.
20. Tey S.K., Kennedy G.A., Cromer D., Davenport M.P., Walker S., Jones L.I., Crough T., Durrant S.T., Morton J.A., Butler J.P., Misra A.K., Hill G.R., Khanna R. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One 2013, 8:e74744. 10.1371/journal.pone.0074744.
21. Ariza-Heredia E.J., Nesher L., Chemaly R.F. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014, 342:1-8. 10.1016/j.canlet.2013.09.004.
22. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 2003, 9:543-558. 10.1016/s1083-8791(03) 00287-8.
23. Sissons J.G., Wills M.R. How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future. Med. Microbiol. Immunol. 2015, 204:307-316. 10.1007/s00430-015-0415-0.
24. Lacey S.F., Diamond D.J., Zaia J.A. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol. Blood Marrow Transplant. 2004, 10:433-447. 10.1016/j.bbmt.2003.12.004.
25. Tan B.H. Cytomegalovirus treatment. Curr. Treat. Options Infect. Dis. 2014, 6:256-270. 10.1007/s40506-014-0021-5.
26. Bhutani D., Dyson G., Manasa R., Deol A., Ratanatharathorn V., Ayash L., Abidi M., Lum L.G., Al-Kadhimi Z., Uberti J.P. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. Biol. Blood Marrow Transplant. 2015, 21:159-164. 10.1016/j.bbmt.2014.10.004.